Summary of Study ST000525

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000387. The data can be accessed directly via it's Project DOI: 10.21228/M81G7P This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000525
Study TitleEffects of Curcumin Supplementation on the Non‐Esterified Fatty Acids concentration of Older Adults: Relation to Vascular Function (part 2)
Study SummaryPerform non-esterified fatty acid concentrations metabolite analysis related to nitric oxide biology, oxidative stress and inflammation in plasma before and after 12 weeks of oral curcumin (2000 mg/d) or placebo (double-blind, randomized) in men and women aged 45-79 years who are free from clinical cardiovascular disease.
Mayo Clinic
Last NameSeals
First NameDouglas
AddressDepartment of Integrative Physiology University of Colorado Boulder, CO 80309
Submit Date2016-12-14
Analysis Type DetailLC-MS
Release Date2018-12-11
Release Version1
Douglas Seals Douglas Seals application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000387
Project DOI:doi: 10.21228/M81G7P
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Effects of Curcumin Supplementation on the Plasma Metabolome of Older Adults: Relation to Vascular Function
Project Summary:Age is the major risk factor for cardiovascular diseases (CVD). Two key contributors to the increased risk of CVD in middle-aged and older (MA/O) adults are stiffening of the large elastic arteries and the development of vascular endothelial dysfunction, indicated by impaired nitric oxide (NO)-induced endothelium-dependent dilation (EDD). The mechanisms by which aging causes arterial dysfunction are incompletely understood, but involve reductions in NO bioavailability associated with the development of oxidative stress and inflammation. Thus, establishing novel strategies to reduce arterial stiffness and increase vascular endothelial function in MA/O adults by increasing NO bioavailability and reducing oxidative stress and inflammation are a high biomedical research priority. Curcumin is a naturally occurring phenol found in the Indian spice turmeric that improves physiological function in animal models of age-related diseases and is a promising nutraceutical for intervention for promoting healthy aging. Our preclinical results indicate that chow supplemented with curcumin reduces aortic pulse wave velocity (PWV), the most common and clinically important measure of large elastic artery stiffness, restores NO-mediated EDD and reduces arterial oxidative stress and inflammation in old C57/BL6 mice. Preliminary data from our recently funded NIH R21 pilot grant indicate that curcumin supplementation improves vascular function in humans. It is possible that changes in the circulating (plasma) metabolome with oral curcumin supplementation will provide insight into novel metabolic mechanisms by which curcumin may improve vascular function. The goal of this project is to identify key metabolic pathways that change with oral curcumin supplementation and to relate those changes with improvements in vascular function in MA/O adults with initial endothelial dysfunction. Metabolomic analysis of plasma samples at baseline also may produce unique molecular signatures that predict responsiveness (changes in vascular function) to curcumin supplementation among individuals.
Institute:Mayo Clinic
Last Name:Seals
First Name:Douglas
Address:Department of Integrative Physiology University of Colorado Boulder, CO 80309


Subject ID:SU000547
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human


Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id group Time point
SA027537ms5534-29Old-Curcumin Post
SA027538ms5589-15Old-Curcumin Post
SA027539ms5589-22Old-Curcumin Post
SA027540ms5534-15Old-Curcumin Post
SA027541ms5534-18Old-Curcumin Post
SA027542ms5534-27Old-Curcumin Post
SA027543ms5534-20Old-Curcumin Post
SA027544ms5534-22Old-Curcumin Post
SA027545ms5589-27Old-Curcumin Post
SA027546ms5589-29Old-Curcumin Post
SA027547ms5534-3Old-Curcumin Post
SA027548ms5589-3Old-Curcumin Post
SA027549ms5589-25Old-Curcumin Post
SA027550ms5589-5Old-Curcumin Post
SA027551ms5534-10Old-Curcumin Post
SA027552ms5534-8Old-Curcumin Post
SA027553ms5534-26Old-Curcumin Pre
SA027554ms5589-14Old-Curcumin Pre
SA027555ms5589-4Old-Curcumin Pre
SA027556ms5534-28Old-Curcumin Pre
SA027557ms5534-19Old-Curcumin Pre
SA027558ms5534-9Old-Curcumin Pre
SA027559ms5589-24Old-Curcumin Pre
SA027560ms5534-7Old-Curcumin Pre
SA027561ms5589-26Old-Curcumin Pre
SA027562ms5534-2Old-Curcumin Pre
SA027563ms5534-14Old-Curcumin Pre
SA027564ms5589-28Old-Curcumin Pre
SA027565ms5534-21Old-Curcumin Pre
SA027566ms5589-2Old-Curcumin Pre
SA027567ms5534-17Old-Curcumin Pre
SA027568ms5589-21Old-Curcumin Pre
SA027569ms5589-18Old-Placebo Post
SA027570ms5589-10Old-Placebo Post
SA027571ms5589-13Old-Placebo Post
SA027572ms5589-20Old-Placebo Post
SA027573ms5589-8Old-Placebo Post
SA027574ms5534-32Old-Placebo Post
SA027575ms5534-34Old-Placebo Post
SA027576ms5589-32Old-Placebo Post
SA027577ms5589-34Old-Placebo Post
SA027578ms5534-25Old-Placebo Post
SA027579ms5534-13Old-Placebo Post
SA027580ms5589-36Old-Placebo Post
SA027581ms5534-5Old-Placebo Post
SA027582ms5534-36Old-Placebo Post
SA027583ms5534-4Old-Placebo Pre
SA027584ms5534-24Old-Placebo Pre
SA027585ms5589-19Old-Placebo Pre
SA027586ms5534-12Old-Placebo Pre
SA027587ms5589-35Old-Placebo Pre
SA027588ms5589-17Old-Placebo Pre
SA027589ms5534-31Old-Placebo Pre
SA027590ms5589-7Old-Placebo Pre
SA027591ms5589-31Old-Placebo Pre
SA027592ms5589-33Old-Placebo Pre
SA027593ms5534-33Old-Placebo Pre
SA027594ms5534-35Old-Placebo Pre
SA027595ms5589-9Old-Placebo Pre
SA027596ms5589-12Old-Placebo Pre
SA027597ms5589-37young Baseline
SA027598ms5589-30young Baseline
SA027599ms5589-1young Baseline
SA027600ms5534-23young Baseline
SA027601ms5534-16young Baseline
SA027602ms5534-11young Baseline
SA027603ms5534-6young Baseline
SA027604ms5534-30young Baseline
SA027605ms5534-37young Baseline
SA027606ms5589-16young Baseline
SA027607ms5589-11young Baseline
SA027608ms5589-6young Baseline
SA027609ms5534-1young Baseline
SA027610ms5589-23young Baseline
Showing results 1 to 74 of 74


Collection ID:CO000541
Collection Summary:Healthy men & women aged 45-79 without clinical CVD, but with below normal baseline endothelial dysfunction (FMDBA < 7%).
Sample Type:Blood


Treatment ID:TR000561
Treatment Summary:A 12-week randomized, double-blind, placebo controlled study will be conducted. After CTRC screening for inclusion/exclusion criteria, qualified subjects will be randomly assigned to 1 of 2 groups. The investigators involved in the acquisition and analysis of key outcomes will be blinded to the curcumin intake status of the subjects. With the assistance of dietary monitoring from the UC-Boulder CTRC bionutritionists, subjects will maintain their baseline diet with either unchanged (control) or enhanced curcumin intake delivered as capsules (Longvida®, Verdure Sciences): Group 1 = placebo (inert substances); Group 2 = curcumin (2000mg curcumin/day). Extensive published work has established that the curcumin dose of 2000 mg/day is well tolerated and safe. Sessions 1 & 2: Screening measurements. Session 3: Baseline measurements and blood draw. Sessions 4-8 (every other week to assess adherence and overall subject well-being): Body weight, BP, adherence, discuss any problems. Session 9: Identical to session 3 (stop intake of capsules after completion of post-testing).

Sample Preparation:

Sampleprep ID:SP000554
Sampleprep Summary:Venous blood sampling. All blood samples are handled in a similar time frame and immediately spun to extract plasma and stored in our -80 freezer until ready for analysis. NEFA concentrations were measured.

Combined analysis:

Analysis ID AN000803
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1290 Infinity
Column Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
MS instrument type Triple quadrupole
MS instrument name Agilent 6460 QQQ
Units uM


Chromatography ID:CH000578
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
Chromatography Type:Reversed phase


MS ID:MS000710
Analysis ID:AN000803
Instrument Name:Agilent 6460 QQQ
Instrument Type:Triple quadrupole